Advertisement

Topics

Lynparza Meets Primary Endpoint in Phase 3 Trial in BRCA-Mutated Metastatic Breast Cancer

09:44 EST 17 Feb 2017 | Speciality Pharma Journal

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.1 Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement …

Original Article: Lynparza Meets Primary Endpoint in Phase 3 Trial in BRCA-Mutated Metastatic Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Lynparza Meets Primary Endpoint in Phase 3 Trial in BRCA-Mutated Metastatic Breast Cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...